Abiopharma

🔍 Dambkowski Carl (Executive)

Company: Apogee Therapeutics, Inc. (APGE)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 83,690 shares of Stock Option (Right to Buy) at $75.78 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-02 | equity_swap_involved: 0 | shares_owned_after: 83,690.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: This option represents the right to purchase 83,690 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer.